Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases.

Abstract:

BACKGROUND:Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to each clinical form is still limited. OBJECTIVE:To assess the whole transcriptome of blood leukocytes from patients with remittent-recurrent (RRMS) and secondary-progressive (SPMS) forms to explore the gene expression profile of each form. METHODS:Total RNA was obtained and sequenced in Illumina HiSeq platform. Reads were aligned to human genome (GRCh38/hg38), BAM files were mapped and differential expression was obtained with DeSeq2. Up or downregulated pathways were obtained through Ingenuity IPA. Pro-inflammatory cytokines levels were also assessed. RESULTS:The transcriptome was generated for nine patients (6 SPMS and 3 RRMS) and 5 healthy controls. A total of 731 and 435 differentially expressed genes were identified in SPMS and RRMS, respectively. RERE, IRS2, SIPA1L1, TANC2 and PLAGL1 were upregulated in both forms, whereas PAD2 and PAD4 were upregulated in RRMS and downregulated in SPMS. Inflammatory and neuronal repair pathways were upregulated in RRMS, which was also observed in cytokine analysis. Conversely, SPMS patients presented IL-8, IL-1, Neurothrophin and Neuregulin pathways down regulated. CONCLUSIONS:Overall, the transcriptome of RRMS and SPMS clearly indicated distinct inflammatory profiles, where RRMS presented marked pro-inflammatory profile but SPMS did not. SPMS individuals also presented a decrease on expression of neuronal repair pathways.

authors

Nali LH,Olival GS,Sousa FTG,de Oliveira ACS,Montenegro H,da Silva IT,Dias-Neto E,Naya H,Spangenberg L,Penalva-de-Oliveira AC,Romano CM

doi

10.1016/j.msard.2020.102243

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

102243

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(20)30319-9

journal_volume

44

pub_type

杂志文章
  • Assessing cognitive performance in radiologically isolated syndrome.

    abstract:BACKGROUND:Radiologically isolated syndrome (RIS) is defined as the occurrence of incidental brain MRI lesions suggestive of multiple sclerosis (MS) in otherwise healthy subjects without any signs or symptoms that could indicate to the disease. We evaluated cognitive performance in a cohort of RIS patients. METHODS:A ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.04.030

    authors: Menascu S,Stern M,Aloni R,Kalron A,Magalshvili D,Achiron A

    更新日期:2019-07-01 00:00:00

  • Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.

    abstract:BACKGROUND:The 2015 International Panel for neuromyelitis optica (NMO) spectrum disorders (NMOSD) diagnosis (IPND) criteria was recently proposed. However, because there are no studies evaluating application of the IPND criteria in Latin American populations, we aimed to assess whether these new criteria improve the di...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.01.001

    authors: Carnero Contentti E,Soto de Castillo I,Daccach Marques V,López PA,Antunes Barreira A,Armas E,de Aquino Cruz C,Rubstein A,Lavigne Moreira C,Molina OM,Soto A,Tkachuk V

    更新日期:2018-02-01 00:00:00

  • Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.

    abstract:BACKGROUND:Numerous factors can affect multiple sclerosis (MS) patients' quality of life (QoL). We investigated how physical impairment, upper extremity function, cognitive impairment, cognitive reserve, symptoms of psychological distress, depression, fatigue as well as age and disease duration contribute to patient-re...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.049

    authors: Yalachkov Y,Soydaş D,Bergmann J,Frisch S,Behrens M,Foerch C,Gehrig J

    更新日期:2019-05-01 00:00:00

  • Impaired central drive to plantarflexors and minimal ankle proprioceptive deficit in people with multiple sclerosis.

    abstract:BACKGROUND:A common and disruptive symptom of multiple sclerosis is difficulty in walking. Deficits in ankle proprioception and in plantarflexor muscle function may contribute to these mobility issues. In this study, ankle proprioceptive ability and plantarflexor performance of people with multiple sclerosis (PwMS) wer...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102584

    authors: Djajadikarta ZJ,Dongés SC,Brooks J,Kennedy DS,Gandevia SC,Taylor JL

    更新日期:2020-11-01 00:00:00

  • Linking Cognitive Impairment to Neuroinflammation in Multiple Sclerosis using neuroimaging tools.

    abstract::Multiple sclerosis (MS) is a complex chronic immune disease in the central nervous system, causing neurological disability among young and middle-aged adults. Impaired cognition is now emerging as a major clinical symptom being present in more than 50% of MS patients. Recent data support that neuroinflammation mediate...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102622

    authors: Barros C,Fernandes A

    更新日期:2020-11-14 00:00:00

  • CNS demyelination during tofacitinib therapy: First report.

    abstract::Iatrogenic demyelination is a distinct clinical subtype of central nervous system inflammatory disorders. The Janus kinase inhibitor, tofacitinib, is an oral disease-modifying antirheumatic drug that has shown contradictory effects on multiple sclerosis in animal models. In this report, we describe a novel case of rev...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102568

    authors: Massoud F,Ismail II,Al-Hashel JY,Abboud H

    更新日期:2020-11-01 00:00:00

  • Mesenchymal stem cells in experimental autoimmune encephalomyelitis model of multiple sclerosis: A systematic review and meta-analysis.

    abstract:BACKGROUND/AIMS:Mesenchymal stem cells (MSCs) transplantation has been considered a possible therapeutic method for Multiple Sclerosis (MS). However, no quantitative data synthesis of MSCs therapy for MS exists. We conducted a systematic review and meta-analysis to evaluate the effects of MSCs in experimental autoimmun...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102200

    authors: Yanwu Y,Meiling G,Yunxia Z,Qiukui H,Birong D

    更新日期:2020-09-01 00:00:00

  • Are fatigue scales the same? A content comparison using the International Classification of Functioning, Disability and Health.

    abstract:BACKGROUND:Fatigue is a common impairment in a wide range of disorders. Numerous fatigue scales have been designed in an attempt to quantify this impairment without any clear distinction between them. The International Classification of Functioning, Disability and Health (ICF) is a useful tool for content comparison of...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102596

    authors: Alghwiri AA,Almhdawi KA,Marchetti G

    更新日期:2020-11-01 00:00:00

  • Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study.

    abstract:BACKGROUND:Growing evidence supports the efficacy of restorative cognitive training in people with multiple sclerosis (PwMS), but the effects vary across individuals. Differences in treatment efficacy may be related to baseline individual differences. We investigated clinical characteristics and MRI variables to predic...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.026

    authors: Fuchs TA,Ziccardi S,Dwyer MG,Charvet LE,Bartnik A,Campbell R,Escobar J,Hojnacki D,Kolb C,Oship D,Pol J,Shaw MT,Wojcik C,Yasin F,Weinstock-Guttman B,Zivadinov R,Benedict RHB

    更新日期:2019-09-01 00:00:00

  • Antecedent anti-NMDA receptor encephalitis in two patients with multiple sclerosis.

    abstract::Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder characterised by psychiatric symptoms, movement disorder and seizures often evolving into a severe encephalopathy. An overlap has recently been recognised between anti-NMDAR encephalitis and inflammatory demyelinating disorders, particul...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.12.009

    authors: Baheerathan A,Brownlee WJ,Chard DT,Shields K,Gregory R,Trip SA

    更新日期:2017-02-01 00:00:00

  • Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.

    abstract:BACKGROUND:A high percentage of patients with multiple sclerosis present cognitive alterations. Because 4-aminopyridine improves nerve conduction and efficient synaptic connection could improve cognitive dysfunction. OBJECTIVE:To evaluate the efficacy on cognitive performance and safety of 4-aminopyridine administered...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.msard.2018.12.026

    authors: Arreola-Mora C,Silva-Pereyra J,Fernández T,Paredes-Cruz M,Bertado-Cortés B,Grijalva I

    更新日期:2019-02-01 00:00:00

  • A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics.

    abstract::Randomized placebo-controlled clinical trials have been considered the most rigorous method of evaluating the efficacy of novel treatment interventions. The first effective disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) were approved in the 1990s after a number of pivotal placebo-...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2016.03.019

    authors: Solomon AJ,Bernat JL

    更新日期:2016-05-01 00:00:00

  • Real-time assessment of daytime sleepiness in drivers with multiple sclerosis.

    abstract:BACKGROUND:Daytime sleepiness is a common symptom of multiple sclerosis (MS) that may jeopardize safe driving. Our aim was to compare daytime sleepiness, recorded in real-time through eyelid tracking, in a simulated drive between individuals with MS (iwMS) and healthy controls. METHODS:Fifteen iwMS (age = median (Q1 -...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102607

    authors: Devos H,Alissa N,Lynch S,Sadeghi M,Akinwuntan AE,Siengsukon C

    更新日期:2020-10-31 00:00:00

  • Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes.

    abstract:BACKGROUND:The appropriate treatment target in multiple sclerosis (MS) is unclear. Lack of magnetic resonance imaging (MRI) lesion activity, a component of the no evidence of disease activity concept, has been proposed as a treatment target in MS. We used our MS database to investigate whether aggressively pursuing MRI...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.07.017

    authors: Conway DS,Thompson NR,Cohen JA

    更新日期:2016-09-01 00:00:00

  • Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial.

    abstract:BACKGROUND:Cognitive impairment is common in multiple sclerosis (MS), but deficits tend to be more pronounced in progressive MS, negatively impacting daily functional capacity. Despite this, most cognitive rehabilitation (CR) interventions to date have focused on relapsing-remitting MS (RRMS). Moreover, information on ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.101932

    authors: Messinis L,Kosmidis MH,Nasios G,Konitsiotis S,Ntoskou A,Bakirtzis C,Grigoriadis N,Patrikelis P,Panagiotopoulos E,Gourzis P,Malefaki S,Papathanasopoulos P

    更新日期:2020-01-07 00:00:00

  • Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.

    abstract:BACKGROUND:The discovery of two immunoglobulin G (IgG) antibodies against aquaporin 4 (anti-AQP4) and myelin oligodendrocyte glycoprotein (anti-MOG) has led to the distinction of the disorders anti-AQP4 immunoglobulin G positive neuromyelitis spectrum disorder (AQP4-IgG+ NMOSD) and anti-MOG associated disorder (MOGAD)....

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102718

    authors: Rempe T,Tarhan B,Rodriguez E,Viswanathan VT,Gyang TV,Carlson A,Tuna IS,Rees J

    更新日期:2020-12-24 00:00:00

  • The epidemiology of multiple sclerosis in the Scottish Highlands: Prevalence, incidence and time to confirmed diagnosis and treatment initiation.

    abstract:INTRODUCTION:Although multiple sclerosis (MS) is frequent in the northern hemisphere, there have not been recent epidemiological studies in the Scottish Highlands about MS. OBJECTIVES:To get updated data regarding MS prevalence, incidence and mortality in the Highlands. Time between symptom onset and MS diagnosis was ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102657

    authors: Carod-Artal FJ

    更新日期:2020-11-28 00:00:00

  • PER3 VNTR polymorphism in Multiple Sclerosis: A new insight to impact of sleep disturbances in MS.

    abstract:BACKGROUND:Multiple Sclerosis (MS) is a degenerative disease of central nervous system caused by an immune response against the myelin. About half of MS patients suffers from sleep disturbances. The circadian clock genes such as PER3 controls circadian rhythm and sleep. Due to the role of PER3 in sleep disturbances and...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.07.005

    authors: Golalipour M,Maleki Z,Farazmandfar T,Shahbazi M

    更新日期:2017-10-01 00:00:00

  • Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.

    abstract:INTRODUCTION:Italy has been the first European country severely affected by the COVID-19 pandemic. OBJECTIVE:To analyze the incidence of the clinical presentations suggestive for COVID-19 infection among patients with Multiple Sclerosis in the province of Lecco, in the North Italy, the closest province capital to Berg...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102453

    authors: Mantero V,Abate L,Balgera R,Basilico P,Salmaggi A,Cordano C

    更新日期:2020-11-01 00:00:00

  • Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder.

    abstract:BACKGROUND:Few data exists on paediatric neuromyelitis optica spectrum disorder (NMOSD). Here, we investigated the clinical presentation, treatment responses and long-term prognoses in a large cohort of patients with NMOSD and compared between children and adults with aquaporin-4 antibody (AQP4-IgG). METHODS:A retrosp...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.msard.2018.12.038

    authors: Zhou Y,Zhong X,Shu Y,Cui C,Wang J,Wang Y,Li X,Chen Z,Peng L,Kermode A,Qiu W

    更新日期:2019-02-01 00:00:00

  • Real-world incidence of fingolimod-associated macular oedema.

    abstract:BACKGROUND:Fingolimod (Gilenya, Novartis, Basel Switzerland) 0.5 mg orally once-daily is widely used for relapsing-remitting multiple sclerosis. Patients are usually screened four months after starting fingolimod for fingolimod-associated macular oedema (FAME). Large registration trials with stringent eligibility crite...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102125

    authors: Goh LY,Kirthi V,Silber E,Harvey JP,Jackson TL

    更新日期:2020-07-01 00:00:00

  • Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis.

    abstract:BACKGROUND:Peak width of skeletonized mean diffusivity (PSMD) is a novel and fully automated, MRI biomarker, which has shown clinical relevance in cerebral small vessel diseases (SVD). We aimed here to assess PSMD levels across the brain of patients with multiple sclerosis (MS), in comparison to normal controls (NC) an...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.011

    authors: Vinciguerra C,Giorgio A,Zhang J,Di Donato I,Stromillo ML,Tappa Brocci R,Federico A,Dotti MT,De Stefano N

    更新日期:2019-01-01 00:00:00

  • Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.

    abstract:BACKGROUND:Patient-reported outcomes (PROs) provide information on treatment effects from the patient's perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.msard.2016.11.005

    authors: Liu Y,Vollmer T,Havrdova E,Riester K,Lee A,Phillips G,Wang P,Sabatella G

    更新日期:2017-01-01 00:00:00

  • The relation between memory and decision-making in multiple sclerosis patients.

    abstract:BACKGROUND:Impairments in long-term and working memory are widespread in Multiple Sclerosis (MS), setting on in early disease stages. These memory impairments may limit patients' ability to take informed and competent medical decisions, too. In healthy populations, memory abilities predict decision quality across a wid...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101433

    authors: Hoffmann JA,Bareuther L,Schmidt R,Dettmers C

    更新日期:2020-01-01 00:00:00

  • The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis.

    abstract:INTRODUCTION:Some studies have indicated the importance of considering smoking, vitamin D deficiency and obesity as negative prognostic factors for clinical and MRI outcomes in multiple sclerosis (MS). This study aimed to evaluate the possible effects of these modifiable risk factors on brain MRI lesion burden of patie...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101886

    authors: Lorefice L,Destro F,Fenu G,Mallus M,Gessa I,Sechi V,Barracciu MA,Frau J,Coghe G,Carmagnini D,Marrosu MG,Saba L,Cocco E

    更新日期:2019-12-09 00:00:00

  • Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review.

    abstract:BACKGROUND:Considering the multiple treatments approved for multiple sclerosis (MS) by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a treatment strategy for patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) can be challenging. To date, an overv...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.101929

    authors: Visser LA,Louapre C,Uyl-de Groot CA,Redekop WK

    更新日期:2020-01-02 00:00:00

  • Neural cell adhesion molecules in brain plasticity and disease.

    abstract::Neural cell adhesion molecule (NCAM) has been studied extensively. But it is only in recent times that interest in this molecule has shifted to conditions such as Alzheimer's disease, Multiple Sclerosis and Schizophrenia, focusing on its role in neurodegeneration and abnormal neurodevelopment. NCAM is important in neu...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2012.08.002

    authors: Gnanapavan S,Giovannoni G

    更新日期:2013-01-01 00:00:00

  • The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

    abstract:OBJECTIVE:Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced t...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102279

    authors: Baker D,Pryce G,James LK,Marta M,Schmierer K

    更新日期:2020-09-01 00:00:00

  • Positive association of herpes simplex virus-IgG with multiple sclerosis: A systematic review and meta-analysis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the central nervous system (CNS), and whether herpes simplex virus (HSV) infection is associated with the development of MS remains controversial. We aimed to investigate potential associations between MS or clinically i...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102633

    authors: Xu L,Zhang LJ,Yang L,Yang CS,Yi M,Zhang SN,Wang N,Huang CN,Liu MQ

    更新日期:2020-11-19 00:00:00

  • Pain-related illness intrusiveness is associated with lower activity engagement among persons with multiple sclerosis.

    abstract:BACKGROUND:Pain can interfere with the daily functioning of persons with multiple sclerosis (PwMS). Furthermore, beliefs about pain and activity engagement are reliably associated with persons' experience of chronic pain. This study aimed to explore the extent to which different aspects of PwMS' activity engagement is ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101882

    authors: Gromisch ES,Kerns RD,Beauvais J

    更新日期:2020-02-01 00:00:00